Synthesis of a novel polymer bile salts-(polyethylene glycol) 2000-bile salts and its application to the liver-selective targeting of liposomal DDB

Drug Development and Industrial Pharmacy

Volumn 36, Issue 6, 2010, Pages 657-665

  Chen, Zhi Peng ^a,b   Zhu, Jia Bi ^b   Chen, Hong Xuan ^c   Xiao, Yan Yu ^b   Feng, Ming Sheng ^b   Cai, Hao ^a   Chen, Jun ^a   Cai, Bao Chang ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c HENAN UNIVERSITY   (China)

Author keywords

Bile salts (polyethylene glycol)2000 bile salts; DDB; Liposome; Liver targeting; Targeted parameters

Indexed keywords

4,4' DIMETHOXY 5,6,5',6' BI(METHYLENEDIOXY) 2,2' BICARBOMETHOXYBIPHENYL LIPOSOME; BILE SALT; LIPOSOME; MACROGOL 2000; PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; LIVER; LIVER PARENCHYMA; MALE; NONHUMAN; PHYSICAL CHEMISTRY; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

ANIMALS; BILE ACIDS AND SALTS; DRUG DELIVERY SYSTEMS; HYDROCARBONS, CHLORINATED; LIPOSOMES; LIVER; MALE; MICE; POLYETHYLENE GLYCOLS; POLYMERS; RATS; RATS, WISTAR;

EID: 77952506018     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903410342     Document Type: Article

References (36)

1. Vyas SP, Subhedar R, Jain S. (2006). Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver. J Pharm Pharmacol, 58:321-6.
2. Redhead HM, Davis SS, Illum L. (2001). Drug delivery in poly (lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: In vitro characterisation and in vivo evaluation. J Control Release, 70:353-63.
3. Meijer DK, Jansen RW, Molema G. (1992). Drug targeting systems for antiviral agents: Options and limitations. Antiviral Res, 18:215-58.
4. Erion MD, van Poelje PD, Mackenna DA, Colby TJ, Montag AC, Fujitaki JM, et al. (2005). Liver-targeted drug delivery using HepDirect prodrugs. J Pharmacol Exp Ther, 312:554-60.
5. Kende M, Alving CR, Rill WL, Swartz GM, Jr., Canonico PG. (1985). Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice. Antimicrob Agents Chemother, 27:903-7. (Pubitemid 15062733)
6. Lambros MP, Abbas SA, Dunn ST, Raja T, Pento T. (2002). Targeting hepatocytes with liposomal interferon-alpha: Effect on metallothionein gene induction. Res Commun Mol Pathol Pharmacol, 112:50-8.
7. Shi J, Yan WW, Qi XR, Yang L, Zhang L. (2004). Biodistribution and hepatocytes targeting of cationic liposomes surfacemodified with sterylglucoside and golyethylene glycol. Yao Xue Xue Bao, 39:551-5.
8. Wu D, Ji S, Wu Y, Ju Y, Zhao Y. (2007). Design, synthesis, and antitumor activity of bile acid-polyamine-nucleoside conjugates. Bioorg Med Chem Lett, 17:2983-6.
9. Kramer W, Wess G. (1996). Bile acid transport systems as pharmaceutical targets. Eur J Clin Invest, 26:715-32.
10. Kramer W, Wess G, Enhsen A, Falk E, Hoffmann A, Neckermann G, et al. (1997). Modified bile acids as carriers for peptides and drugs. J Control Release, 46:17-30.
11. Pütz G, Schmider W, Nitschke R, Kruz G, Blum HE. (2005). Synthesis of phospholipid-conjugated bile salts and interaction of bile salt-coated liposomes with cultured hepatocytes. J Lipid Res, 46:2325-38.
12. Levy G. (1987). Targeted drug delivery-some pharmacokinetic considerations. Pharm Res, 4:3-4.
13. Barenholz Y. (2001). Liposome applications: Problems and prospects. Curr Opin Colloid Interface Sci, 6:66-77.
14. Ceh B, Winterhalter M, Frederik PM, Vallner JJ, Lasic DD. (1997). Stealth liposomes: From theory to product. Adv Drug Deliv Rev, 24:165-77.
15. Garbuzenko O, Barenholz Y, Priev A. (2005). Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem Phys Lipids, 135:117-29.
16. Popielarski SR, Pun SH, Davis ME. (2005). A nanoparticlebased model delivery system to guide the rational design of gene delivery to the liver. 1. Synthesis and characterization. Bioconjug Chem, 16:1063-70.
17. Shimizu K, Maitani Y, Takayama K, Nagai T. (1996). Characterization of dipalmitoylphosphatidylcholine liposomes containing a soybean-derived sterylglucoside mixture by differential scanning calorimetry, Fourier transform infrared spectroscopy, and enzymatic assay. J Pharm Sci, 85:741-4.
18. Kawakami S, Munakata C, Fumoto S, Yamashita F, Hashida M. (2001). Novel galactosylated liposomes for hepatocyte-selective targeting of lipophilic drugs. J Pharm Sci, 90:105-13.
19. Frisch B, Carrière M, Largeau C, Mathey F, Masson C, Schuber F, et al. (2004). A new triantennary galactose-targeted PEGylated gene carrier, characterization of its complex with DNA, and transfection of hepatoma cells. Bioconjug Chem, 15:754-64.
20. Bülbül M, Saracoglu N, Küfrevioglu OI, Ciftçi M. (2002). Bile acid derivatives of 5-amino-1, 3, 4-thiadiazole-2-sulfonamide as new carbonic anhydrase inhibitors: Synthesis and investigation of inhibition effects. Bioorg Med Chem, 10:2561-7.
21. Cui S, Wang M. (2002). Anti-HBV efficacy of bifendate in treatment of chronic hepatitis B, a primary study. Zhonghua Yi Xue Za Zhi, 82:538-40.
22. Yao L, Zou LY, Tang LB. (2005). Effects of dimethyl diphenyl bicarboxylate on the acute liver injury induced by carbon tetrachloride in rats. J Guangdong Med Coll, 23:651-3.
23. el-Sawy SA, el-Shafey AM, el-Bahrawy HA. (2002). Effect of dimethyl diphenyl bicarboxylate on normal and chemicallyinjured liver. East Mediterr Health J, 8:95-104.
24. Qi X, Wang X, Wang L, Wang Q, Cheng S, Suo J, et al. (2005). A solid-phase approach to DDB derivatives. Eur J Med Chem, 40:805-10.
25. Chi SC, Yeom DI, Kim SC, Park ES. (2003). A polymeric micellar carrier for the solubilization of biphenyl dimethyl dicarboxylate. Arch Pharm Res, 26:173-81.
26. Harris JM, Struck EC, Case MG, Paley MS, Yalpani M, Van Alstine JM, et al. (1984). Synthesis and characterization of poly (ethylene glycol) derivatives. J Polym Sci Polym Chem Ed, 22:341-52.
27. Bangham AD, Standish MM, Watkins JC. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol, 13:238-52.
28. Chen ZP, Zhu JB, Chen HX, Xiao YY. (2007). A simple HPLC method for the determination of bifendate: Application to a pharmacokinetic study of bifendate liposome. J Chromatogr B, 857:246-50.
29. Shah NB, Sheth BB. (1972). A method for study of timed-release films. J Pharm Sci, 61:412-6.
30. Gupta PK, Hung CT. (1989). Quantitative evaluation of targeted drug delivery systems. Int J Pharm, 56:217-29.
31. Sliedregt LA, Rensen PC, Rump ET, van Santbrink PJ, Bijsterbosch MK, Valentijn AR, et al. (1999). Design and synthesis of novel amphiphilic dendritic galactoside for selective targeting of liposomes to the hepatic asialoglycoprotein receptor. J Med Chem, 42:609-18.
32. Lange Y, Steck TL. (2008). Cholesterol homeostasis and the escape tendency (activity) of plasma membrane cholesterol. Prog Lipid Res, 47:319-32.
33. Hashizaki K, Taguchi H, Itoh C, et al. (2003). Effects of poly (ethylene glycol) (PEG) chain length of PEG-lipid on the permeability of liposomal bilayer membranes. Chem Pharm Bull, 51:815-20.
34. Sadzuka Y, Nakade A, Tsuruda T, et al. (2003). Study on the characterization of mixed polyethyleneglycol modified liposomes containing doxorubicin. J Control Release, 91:271-80.
35. Sugiyama I, Sadzuka Y. (2007). Characterization of novel mixed polyethyleneglycol modified liposomes. Biol Pharm Bull, 30:208-11.
36. Managit C, Kawakami S, Nishikawa M, et al. (2003). Targeted and sustained drug delivery using PEGylated galactosylated liposomes. Int J Pharm, 266:77-84.